Mizuho upgraded Corvus Pharmaceuticals (CRVS) to Outperform from Neutral with a price target of $12, up from $3.50. The firm significantly raised its estimates for the company’s lead asset soquelitinib in lead indication peripheral T-cell lymphoma, where it is now meaningfully above consensus. The analyst sees “vast potential” in immune diseases for Corvus and tells investors to buy the stock ahead of the upcoming Phase 1 soquelitinib data sets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS: